Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (30)	8/11/1998 1:02:00 PM
From: Biomaven	Respond to of 124

BJ, I heard that there are some cardiovascular side effects of this drug and I wonder if they are mechanism related. If so, then there will be no big splash with this mechanism. All I know is what was reported in the filing: To date, in the limited Phase II clinical studies, LY334370 was observed to reduce or eliminate migraine pain. According to Lilly, no cardiovascular side effects have been observed, although at certain higher doses side effects such as asthenia, dizziness and/or somnolence were observed. -------- If there really are _no_ cardiovascular or other serious side-effects and it works as well as the other triptans, then eventually we could be looking at an OTC drug, which would be a very big splash indeed. Peter

To: Biotech Jim who wrote (30)	9/3/1998 3:36:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 124

BJ, I guess Lilly liked what they saw in the Phase II's: Synaptic, Lilly rise on plans for migraine trial NEW YORK, Sept 3 (Reuters) - Shares of Synaptic Pharmaceutical Corp. (SNAP - news) and its collaboration partner, Eli Lilly and Co. (LLY - news), rose Thursday after the companies said they would move a candidate migraine drug into late-stage clinical trials. Synaptic, based in Paramus, N.J., was up 1-11/16 to 12-9/16 in early afternoon trade. Indianapolis-based Lilly was up 2-1/8 to 71-3/8. The drug, developed by Synaptic, works by selectively stimulating the so-called 5-HT IF receptor, one of many varieties of receptors associated with the neurotransmitter serotonin. Vector Securities analyst Robert Toth said Lilly had given Synaptic's migraine drug clearance for Phase III trials based upon Phase II data from one European trial and two U.S. trials that has not yet been made public. ''We haven't gotten a clear view of the efficacy of the drug,'' Toth said, but added that progression of the experimental compound to Phase III trials was a very positive sign. Hambrecht & Quist drug analyst Richard van den Broek said Synaptic and Lilly had been collaborating on the migraine drug for several years as part of a broader-sweep exploration of serotonin-based drugs. Van den Broek said the drug is believed to be free of cardiovascular side-effects common to existing ''triptan-family'' migraine treatments, such as Glaxo Wellcome Plc's (quote from Yahoo! UK & Ireland: GLXO.L) Imitrex, that simultaneously stimulate numerous types of serotonin receptors. ''Synaptic is a very well-managed company with $70 million in cash and several partnerships with larger drug companies,'' van den Broek said. Synaptic and Merck & Co. (MRK - news) are collaborating on an early-stage trial of a drug for benign prostate hyperplasia. Synaptic is partnered with Warner-Lambert Co. (WLA - news) in a study of galanin receptors believed involved in obesity, depression and other diseases.